BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33146913)

  • 21. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.
    Kobayashi H; Kikuchi E; Mikami S; Maeda T; Tanaka N; Miyajima A; Nakagawa K; Oya M
    BMC Urol; 2014 Jan; 14():5. PubMed ID: 24400640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years.
    Larsson P; Wijkström H; Thorstenson A; Adolfsson J; Norming U; Wiklund P; Onelöv E; Steineck G
    Scand J Urol Nephrol; 2003; 37(3):195-201. PubMed ID: 12775276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Lee A; Lee HJ; Huang HH; Ho H; Chen K
    Int J Urol; 2019 Apr; 26(4):481-486. PubMed ID: 30834632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Environmental and occupational exposures and prognosis in patients with non-muscle-invasive bladder cancer in the Be-Well Study.
    Wang Z; Kwan ML; Haque R; Pratt R; Lee VS; Roh JM; Ergas IJ; Cannavale KL; Loo RK; Aaronson DS; Quesenberry CP; Ambrosone CB; Kushi LH; Tang L
    Am J Epidemiol; 2024 Jun; 193(6):863-873. PubMed ID: 38055616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
    Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
    Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
    EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models.
    Luján S; Santamaría C; Pontones JL; Ruiz-Cerdá JL; Trassierra M; Vera-Donoso CD; Solsona E; Jiménez-Cruz F
    Actas Urol Esp; 2014 Dec; 38(10):647-54. PubMed ID: 24930059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
    Blute ML; Rushmer TJ; Shi F; Fuller BJ; Abel EJ; Jarrard DF; Downs TM
    J Urol; 2015 Nov; 194(5):1214-9. PubMed ID: 26173101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
    de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
    J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
    Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
    Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flexible cystoscopy and Holmium:Yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia.
    Syed HA; Talbot N; Abbas A; MacDonald D; Jones R; Marr TJ; Rukin NJ
    J Endourol; 2013 Jul; 27(7):886-91. PubMed ID: 23537221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic tumour factors affecting recurrence in non muscle invasive bladder cancer: a hospital based study from India.
    Mehta N; Rathore RS; Pillai BS; Sam MP; Moorthy K
    Asian Pac J Cancer Prev; 2015; 16(7):2675-7. PubMed ID: 25854345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.